Compare · AMGN vs PLUR
AMGN vs PLUR
Side-by-side comparison of Amgen Inc. (AMGN) and Pluri Inc. (PLUR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AMGN and PLUR operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- AMGN is the larger of the two at $181.77B, about 7261.5x PLUR ($25.0M).
- Over the past year, AMGN is up 16.8% and PLUR is down 43.4% - AMGN leads by 60.2 points.
- AMGN has been more active in the news (35 items in the past 4 weeks vs 1 for PLUR).
- AMGN has more recent analyst coverage (25 ratings vs 0 for PLUR).
- Company
- Amgen Inc.
- Pluri Inc.
- Price
- $336.77+0.08%
- $2.52-28.06%
- Market cap
- $181.77B
- $25.0M
- 1M return
- -0.33%
- -24.63%
- 1Y return
- +16.78%
- -43.39%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1983
- News (4w)
- 35
- 1
- Recent ratings
- 25
- 0
Amgen Inc.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and a strategic research and development collaboration with Neumora Therapeutics, Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Latest AMGN
- AMGEN TO PRESENT AT JEFFERIES GLOBAL HEALTHCARE CONFERENCE
- Ember LifeSciences announces new strategic investments boosting Series A to $27M
- Director Miles Amy E was granted 665 shares, increasing direct ownership by 13% to 5,640 units (SEC Form 4)
- Director Kullman Ellen Jamison was granted 665 shares, increasing direct ownership by 5% to 14,536 units (SEC Form 4)
- Director Klotman Mary E. was granted 665 shares, increasing direct ownership by 43% to 2,211 units (SEC Form 4)
- Director Jacks Tyler was granted 665 shares, increasing direct ownership by 4% to 18,284 units (SEC Form 4)
- Director Ishrak Omar was granted 665 shares, increasing direct ownership by 10% to 7,359 units (SEC Form 4)
- Director Holley Charles M was granted 665 shares, increasing direct ownership by 5% to 12,799 units (SEC Form 4)
- Director Garland Greg C. was granted 665 shares, increasing direct ownership by 5% to 13,848 units (SEC Form 4)
- Director Eckert Robert was granted 665 shares, increasing direct ownership by 3% to 26,251 units (SEC Form 4)
Latest PLUR
- SEC Form 10-Q filed by Pluri Inc.
- Director Manieu Alexandre Weinstein was granted 625,000 shares (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13D/A filed by Pluri Inc.
- SEC Form DEFA14A filed by Pluri Inc.
- SEC Form DEF 14A filed by Pluri Inc.
- Pluri Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
- Pluri Secures Additional Investment from Chairman Alejandro Weinstein at 30% Premium to Market in a Private Placement
- Pluri Inc. filed SEC Form 8-K: Other Events
- Pluri Secures Global IP Position with China Patent Grant for Large-Scale Immune Cell Expansion, Complementing Prior U.S. Patent
- SEC Form 10-Q filed by Pluri Inc.